6325-94-6

Basic information

• Product Name: 5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE
• Synonyms: 5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE;NSC 31153
• CAS NO: 6325-94-6
• Molecular Formula: C₁₀H₇NO₃S
• Molecular Weight: 221.23248
• Mol File: 6325-94-6.mol
• Article Data: 24

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.542g/cm³
• Refractive Index: 1.744
• CAS DataBase Reference: 5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE(6325-94-6)
• EPA Substance Registry System: 5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE(6325-94-6)

Safety Data

• Hazardous Substances Data: 6325-94-6(Hazardous Substances Data)

Usage

General Description

5-(2-HYDROXY-BENZYLIDENE)-THIAZOLIDINE-2,4-DIONE, also known as Rosiglitazone, is a chemical compound used in the treatment of type 2 diabetes. It belongs to the class of thiazolidinedione drugs and works by increasing the body's sensitivity to insulin. This, in turn, helps to lower blood sugar levels and control diabetes. Rosiglitazone is thought to work by activating the peroxisome proliferator-activated receptors (PPARs) in the body, which play a role in regulating genes involved in glucose and lipid metabolism. However, its use has been limited in some countries due to concerns about its cardiovascular safety profile.

InChI:InChI=1/C10H7NO3S/c12-7-4-2-1-3-6(7)5-8-9(13)11-10(14)15-8/h1-5,12H,(H,11,13,14)

Upstream product

• 90-02-8 salicylaldehyde 
• 17356-08-0 thiourea 
• 79-11-8 chloroacetic acid 
• 2295-31-0 thiazoline-2,4-dione 
• 63671-19-2 chromeno[2,3-d]thiazol-2-one 

Downstream Products

• 1402084-21-2 (Z)-2'-(2-naphthylsulfonyloxy)-5-benzylidene-thiazolidine-2,4-dione 
• 1402084-20-1 (Z)-2'-(1-naphthylsulfonyloxy)-5-benzylidene-thiazolidine-2,4-dione 
• 1402084-19-8 (Z)-2'-(4-biphenylsulfonyloxy)-5-benzylidene-thiazolidine-2,4-dione 
• 1402084-18-7 (Z)-2'-(4-trifluoromethxybenzenesulfonyloxy)-5-benzylidenethiazolidine-2,4-dione 
• 1402084-17-6 (Z)-2'-(4-tert-butylbenzenesulfonyloxy)-5-benzylidene-thiazolidine-2,4-dione 
• 1402084-16-5 (Z)-2'-(4-isopropylbenzenesulfonyloxy)-5-benzylidenethiazolidine-2,4-dione 
• 1402084-15-4 (Z)-2'-(3,4-dimethoxybenzenesulfonyloxy)-5-benzylidenethiazolidine-2,4-dione 
• 1402084-14-3 (Z)-2'-(4-bromobenzenesulfonyloxy)-5-benzylidenethiazolidine-2,4-dione 
• 1402084-13-2 (Z)-2'-(4-fluorobenzenesulfonyloxy)-5-benzylidenethiazolidine-2,4-dione 
• 1307299-61-1 (Z)-5-(2-hydroxybenzylidene)-3-[(7-hydroxy-2-oxo-2H-chromen-4-yl)methyl]thiazolidine-2,4-dione 
• 1020066-75-4 (Z)-5-(2-hydroxybenzylidene)-3-(1-methylcyclohexylmethyl)thiazolidine-2,4-dione 
• 83749-88-6 5-(2-Hydroxybenzyliden)-3-hydroxymethylthiazolidinon-2,4 

Relevant articles and documents

Synthesis and characterization of pine-cone derived carbon-based solid acid: A green and recoverable catalyst for the synthesis of pyra-no_pyrazole, amino-benzochromene, amidoalkyl naphthol and thiazoli-dinedione derivatives

In this report, SO3H-functionalized Carbon nanoparticles (Pine-SO3H) with high acid density have been synthesized by the thermal treatment of sulfuric acid with Pine-Cone as carbon-based at 180oC in a sealed autoclave in a

HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY

The present invention relates to certain heterocyclic compounds of formula (1) that have the ability to inhibit lysine biosynthesis via the diaminopimelate biosynthesis pathway in certain organisms. As a result of this activity these compounds can be used

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors

Several findings propose the altered tau protein network as an important target for Alzheimer's disease (AD). Particularly, two points of pharmacological intervention can be envisaged: inhibition of phosphorylating tau kinase GSK-3β and tau aggregation process. On the basis of this consideration and on our interest in multitarget paradigms in AD, we report on the discovery of 2,4-thiazolidinedione derivatives endowed with such a profile. 28 and 30 displayed micromolar IC50 values toward GSK-3β, together with the capacity of inhibiting AcPHF6 aggregation of 60% and 80% at 10 μM, respectively. In addition, they showed PAMPA-BBB permeability, together with a suitable cellular safety profile. 30 also displayed inhibition of both K18 and full-length tau aggregations. Finally, both compounds were able to improve cell viability in an okadaic acid-induced neurodegeneration cell model. To the best of our knowledge, 28 and 30 are the first balanced, nontoxic, dual-acting compounds hitting tau cascade at two different hubs.